J Clin Densitom. 2026 Feb 17;29(2):101684. doi: 10.1016/j.jocd.2026.101684. Online ahead of print.ABSTRACTINTRODUCTION: Leg length has been found to be a predictor of the risk cardiovascular disease, metabolic disease and type 2 diabetes. Traditional measures of leg-length are conducted by subtracti
No abstractEur J Heart Fail. 2026 Feb 19:xuag012. doi: 10.1093/ejhf/xuag012. Online ahead of print.NO ABSTRACTPMID:41771147 | DOI:10.1093/ejhf/xuag012
No abstractEur J Heart Fail. 2026 Jan 21:xuag021. doi: 10.1093/ejhf/xuag021. Online ahead of print.NO ABSTRACTPMID:41771139 | DOI:10.1093/ejhf/xuag021
Eur J Heart Fail. 2026 Jan 14:xuaf026. doi: 10.1093/ejhf/xuaf026. Online ahead of print.ABSTRACTAIMS: Patients with heart failure and reduced ejection fraction (HFrEF) are frequently exposed to polypharmacy, placing them at risk of potentially inappropriate prescribing (PIP)-defined as use of drugs
No abstractEur J Heart Fail. 2026 Feb 17:xuag046. doi: 10.1093/ejhf/xuag046. Online ahead of print.NO ABSTRACTPMID:41771116 | DOI:10.1093/ejhf/xuag046
No abstractEur J Heart Fail. 2026 Feb 17:xuaf013. doi: 10.1093/ejhf/xuaf013. Online ahead of print.NO ABSTRACTPMID:41771113 | DOI:10.1093/ejhf/xuaf013
Eur J Heart Fail. 2026 Feb 2:xuaf030. doi: 10.1093/ejhf/xuaf030. Online ahead of print.ABSTRACTAIMS: Dilated cardiomyopathy (DCM) encompasses genetic and acquired aetiologies, yet the impact of immune-mediated mechanisms remains unclear. This study investigates the clinical characteristics and outco
Eur J Heart Fail. 2026 Feb 11:xuag042. doi: 10.1093/ejhf/xuag042. Online ahead of print.ABSTRACTRenal artery stenosis due to atherosclerotic renovascular disease (ARVD) is common but under-recognized amongst patients with heart failure and chronic kidney disease (CKD). Whether renal artery stenosis
Eur J Heart Fail. 2026 Jan 17:xuag015. doi: 10.1093/ejhf/xuag015. Online ahead of print.ABSTRACTHeart failure (HF) remains a major global health challenge, characterized by high morbidity, mortality, and healthcare costs despite substantial advances in pharmacological, device-based, and structural t
No abstractEur J Heart Fail. 2026 Jan 8:xuaf004. doi: 10.1093/ejhf/xuaf004. Online ahead of print.NO ABSTRACTPMID:41771103 | DOI:10.1093/ejhf/xuaf004
Eur J Heart Fail. 2026 Feb 4:xuag027. doi: 10.1093/ejhf/xuag027. Online ahead of print.ABSTRACTObesity is prevalent among patients with heart failure (HF), especially in those with preserved ejection fraction (HFpEF), and complicates diagnosis, therapy, and monitoring. It alters haemodynamics, bioma
Eur J Heart Fail. 2026 Jan 8:xuaf008. doi: 10.1093/ejhf/xuaf008. Online ahead of print.ABSTRACTHypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiac disease and a leading cause of heart failure, arrhythmia, and sudden cardiac death in both young and older adults. This consensus doc
Eur J Heart Fail. 2026 Jan 29:xuag024. doi: 10.1093/ejhf/xuag024. Online ahead of print.ABSTRACTPeripartum cardiomyopathy (PPCM) can be a serious condition, presenting with heart failure with reduced ejection fraction towards the end of pregnancy or in the months following delivery. Less than half o
Eur J Heart Fail. 2026 Jan 8:xuaf001. doi: 10.1093/ejhf/xuaf001. Online ahead of print.ABSTRACTAIMS: To evaluate whether circulating N-terminal pro-B type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) can stage hypertensive heart disease (HHD), by assessing their as
No abstractEur J Heart Fail. 2026 Jan 8:xuaf006. doi: 10.1093/ejhf/xuaf006. Online ahead of print.NO ABSTRACTPMID:41771090 | DOI:10.1093/ejhf/xuaf006
Eur J Heart Fail. 2026 Jan 13:xuag004. doi: 10.1093/ejhf/xuag004. Online ahead of print.ABSTRACTThere is strong evidence that hypertension is a major risk factor for heart failure (HF). Hypertension contributes to incident HF through direct and indirect effects. Indirect effects are consequences of
No abstractEur J Heart Fail. 2026 Jan 23:xuaf022. doi: 10.1093/ejhf/xuaf022. Online ahead of print.NO ABSTRACTPMID:41771083 | DOI:10.1093/ejhf/xuaf022
No abstractEur J Heart Fail. 2026 Jan 23:xuag026. doi: 10.1093/ejhf/xuag026. Online ahead of print.NO ABSTRACTPMID:41771074 | DOI:10.1093/ejhf/xuag026
Eur J Heart Fail. 2026 Jan 12:xuaf023. doi: 10.1093/ejhf/xuaf023. Online ahead of print.ABSTRACTAIMS: For many years, fluid and sodium restriction have been considered an essential strategy for achieving effective decongestion in acute heart failure (AHF), but this paradigm has recently been questio
Eur J Heart Fail. 2026 Jan 8:xuaf016. doi: 10.1093/ejhf/xuaf016. Online ahead of print.ABSTRACTAIMS: Heart failure (HF) with preserved (HFpEF) and mildly reduced (HFmrEF) ejection fraction are prevalent, yet frequently underdiagnosed syndromes associated with high morbidity and mortality, impaired q
Eur J Heart Fail. 2026 Jan 22:xuaf027. doi: 10.1093/ejhf/xuaf027. Online ahead of print.ABSTRACTAIMS: Dyspnoea accounts for nearly 5% of emergency department (ED) visits. Our aim was to describe the in-hospital and long-term outcomes of patients admitted to the ED for dyspnoea, based on their underl
Diab Vasc Dis Res. 2026 Mar-Apr;23(2):14791641261431777. doi: 10.1177/14791641261431777. Epub 2026 Mar 2.ABSTRACTObjectiveSodium-glucose cotransporter 2 (SGLT2) inhibitors have been studied for their effects on cardiovascular disease, cognitive impairment, dementia, Parkinson's disease, and cerebrov
Proc Natl Acad Sci U S A. 2026 Mar 10;123(10):e2427234123. doi: 10.1073/pnas.2427234123. Epub 2026 Mar 2.ABSTRACTImmune checkpoint inhibitors (ICIs) have significantly improved the outcome of cancer treatment, but they also expose most patients to a variety of treatment-related adverse events (AEs).
No abstractCirculation. 2026 Mar 3;153(9):613-615. doi: 10.1161/CIRCULATIONAHA.125.077882. Epub 2026 Mar 2.NO ABSTRACTPMID:41770858 | DOI:10.1161/CIRCULATIONAHA.125.077882
